Clinical/Scientific Note

Entacapone-Induced Hepatotoxicity and Hepatic Dysfunction†

  1. Alexander Fisher MD1,
  2. James Croft-Baker MBBS, MRCP1,
  3. Michael Davis MBBS, FRACP1,2,
  4. Patrick Purcell MBBS3,
  5. Allan J. McLean MBBS (Hon I), BMed Sci (Hons I), PhD, FRACP, AFACHSE1,2,4,*

Article first published online: 26 NOV 2002

DOI: 10.1002/mds.10342

Issue

Movement Disorders

Movement Disorders

Volume 17, Issue 6, pages 1362–1365, November/December 2002

Additional Information

How to Cite

Fisher, A., Croft-Baker, J., Davis, M., Purcell, P. and McLean, A. J. (2002), Entacapone-Induced Hepatotoxicity and Hepatic Dysfunction. Movement Disorders, 17: 1362–1365. doi: 10.1002/mds.10342

Author Information

  1. 1

    Department of Geriatric Medicine, The Canberra Hospital, Canberra, Australia

  2. 2

    Canberra Clinical School of the University of Sydney Canberra, Australia

  3. 3

    Therapeutic Goods Administration, Canberra, Australia

  4. 4

    National Ageing Research Institute, University of Melbourne, Royal Melbourne Hospital, and Melbourne Health, Melbourne, Australia

*National Ageing Researach Institute, PO Box 31, Parkville, Victoria 3052, Australia

  1. †

    This article has been slightly modified from the version that appeared on the website in April 2002.

Publication History

  1. Issue published online: 26 NOV 2002
  2. Article first published online: 26 NOV 2002
  3. Manuscript Accepted: 25 JAN 2002
  4. Manuscript Revised: 5 JAN 2002
  5. Manuscript Received: 18 OCT 2001

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (11613K)

Keywords:

  • hepatotoxicity;
  • entacapone;
  • COMT inhibitors

Abstract

We describe 2 patients with Parkinson's disease who developed hepatotoxicity associated with the use of entacapone, a novel, mainly peripheral acting inhibitor of catechol-D-methyltransferase. Hepatotoxicity resolved rapidly with discontinuation of the drug. Analysis of causality in a further case initially linked to entacapone exposure was confounded by conflicting serial adverse reaction reports. © 2002 Movement Disorder Society

View Full Article (HTML) Get PDF (11613K)